Akston Biosciences

Akston Biosciences is focused on developing therapeutics for diabetes.In May 2019, Akston Biosciences had signed a lease for an additional 14,000 square feet of space at the Cummings Center in Beverly, MA and started construction of a new GMP biologics manufacturing facility, a GMP quality control laboratory, and a large scale process development laboratory. The new capabilities would enable the production of GMP drug substance to support the clinical and commercial development.In April 2020, the company closed US $7.6 million Series E financing, including the conversion of US $2.5 million from notes sold previously.In May 2019, the company completed a $2.5 million convertible note financing.In May 2018, the company completed $3.9 million Series D financing, including the conversion of $1.9 million from Notes.In August 2016, the company completed $3.4 million series C financing round.In May 2015, Akston Biosciences completed its $1.6 million series B finan